The following stocks are the leading risers and fallers among London Main Market small-caps on Tuesday.
----------
SMALL-CAP - WINNERS
----------
Solvonis Therapeutics PLC, up 13% at 0.37 pence, 12-month range 0.11p-0.38p. The pharmaceutical company reports positive results from pre-clinical screening of its SVN-SDN-14 programme. The candidates are aimed at treating sufferers of post-traumatic stress disorder. ‘In-vitro screening for SERT, DAT, and NET modulation activity identified three of six synthesised candidates with robust, balanced modulation profiles across all three neurotransmitter systems. These are precisely the mechanistic attributes the programme is targeting to deliver a new class of medicine for trauma-related mental health conditions such as PTSD,’ Solvonis says.
----------
S&U PLC, up 2.9% at 1,928.96 pence, 12-month range 1,230.00p-2,020.00p. The lender focused on motor finance and property bridging believes ‘favourable trends have continued and even accelerated’. ‘As a result, the expected resurgence in profitability for the group is beginning to materialise and is expected to gain momentum in the second half of the year,’ it says in a trading statement for the period from mid-June to the end of July. It also notes a recent motor finance verdict by the UK Supreme Court which believes aids market confidence and stability. It adds: ‘Rejecting the idea that there is a fiduciary relationship (shared by the lender) between broker/dealer and customer, was both good common sense and minimises the risk of contagion to other consumer industries where commissions are paid. It was also heartening to see the Supreme Court handing down the severe criticism the claims management sector has for so long deserved.’
----------
SMALL-CAP - LOSERS
----------
Xaar PLC, down 4.2% at 114.50p, 12-month range 57.60p-142.00p. The industrial inkjet manufacturer reports a widened loss for the first half of 2025, despite revenue growing. Pretax loss stretches to £2.8 million from £2.0 million a year prior. Revenue rises 6.6% to £27.2 million from £25.5 million. Selling, general and administrative expenses increase 15% to G£10.7 million. ‘Our expectations for 2025 remain unchanged despite the additional uncertainty brought by the introduction of tariffs and the continuation of challenging trading conditions reported in March 2025. Our strength is our attractive value proposition centred around the ability to jet highly viscous liquids. We continue to anticipate that revenue will be second half weighted with order volumes expected to grow steadily throughout the year and into FY26,’ Xaar says.
----------
Copyright 2025 Alliance News Ltd. All Rights Reserved.
